Glutamatergic dysfunction in Schizophrenia
Abstract The NMDA-R hypofunction model of schizophrenia started with the clinical observation of the precipitation of psychotic symptoms in patients with schizophrenia exposed to PCP or ketamine. Healthy volunteers exposed to acute low doses of ketamine experienced mild psychosis but also negative a...
Main Authors: | Andreas O. Kruse, Juan R. Bustillo |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-12-01
|
Series: | Translational Psychiatry |
Online Access: | https://doi.org/10.1038/s41398-022-02253-w |
Similar Items
-
Glutamatergic System and Schizophrenia
by: Osman Ozdemir, et al.
Published: (2016-12-01) -
Risk-Conferring Glutamatergic Genes and Brain Glutamate Plus Glutamine in Schizophrenia
by: Juan R. Bustillo, et al.
Published: (2017-06-01) -
Clozapine Reverses Dysfunction of Glutamatergic Neurons Derived From Clozapine-Responsive Schizophrenia Patients
by: Hana Hribkova, et al.
Published: (2022-02-01) -
Altered balance of excitatory and inhibitory learning in a genetically modified mouse model of glutamatergic dysfunction relevant to schizophrenia
by: Sanderson, D, et al.
Published: (2017) -
Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
by: Olga Yu. Fedorenko, et al.
Published: (2022-06-01)